- Home
- EVAX vs CLRB Comparison
EVAX vs CLRB Comparison
Compare EVAX & CLRB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- EVAX
- CLRB
- Stock Information
- Founded
- EVAX 2008
- CLRB 2002
- Country
- EVAX Denmark
- CLRB United States
- Employees
- EVAX N/A
- CLRB N/A
- Industry
- EVAX Biotechnology: Biological Products (No Diagnostic Substances)
- CLRB Biotechnology: Pharmaceutical Preparations
- Sector
- EVAX Health Care
- CLRB Health Care
- Exchange
- EVAX Nasdaq
- CLRB Nasdaq
- Market Cap
- EVAX 15.1M
- CLRB 14.2M
- IPO Year
- EVAX 2021
- CLRB N/A
- Fundamental
- Price
- EVAX $2.61
- CLRB $4.72
- Analyst Decision
- EVAX Strong Buy
- CLRB Hold
- Analyst Count
- EVAX 2
- CLRB 2
- Target Price
- EVAX $10.00
- CLRB N/A
- AVG Volume (30 Days)
- EVAX 121.3K
- CLRB 121.3K
- Earning Date
- EVAX 08-13-2025
- CLRB 08-12-2025
- Dividend Yield
- EVAX N/A
- CLRB N/A
- EPS Growth
- EVAX N/A
- CLRB N/A
- EPS
- EVAX N/A
- CLRB N/A
- Revenue
- EVAX $3,293,000.00
- CLRB N/A
- Revenue This Year
- EVAX N/A
- CLRB N/A
- Revenue Next Year
- EVAX N/A
- CLRB N/A
- P/E Ratio
- EVAX N/A
- CLRB N/A
- Revenue Growth
- EVAX 2555.64
- CLRB N/A
- 52 Week Low
- EVAX $1.20
- CLRB $4.36
- 52 Week High
- EVAX $17.75
- CLRB $68.70
- Technical
- Relative Strength Index (RSI)
- EVAX 49.56
- CLRB 36.75
- Support Level
- EVAX $2.56
- CLRB $4.65
- Resistance Level
- EVAX $3.03
- CLRB $5.15
- Average True Range (ATR)
- EVAX 0.20
- CLRB 0.39
- MACD
- EVAX -0.01
- CLRB 0.12
- Stochastic Oscillator
- EVAX 25.00
- CLRB 19.82
About EVAX Evaxion Biotech
Evaxion AS is in the field of oncology. It used the AI-Immunology platform.
About CLRB Cellectar Biosciences Inc.
Cellectar Biosciences Inc is a clinical-stage biopharmaceutical company. It is focused on the discovery, development, and commercialization of drugs for the treatment of cancer. The company's core objective is to leverage a proprietary phospholipid drug conjugate (PDC) delivery platform to develop PDCs that are designed to specifically target cancer cells and deliver improved efficacy and safety as a result of fewer off-target effects. It has one operating and reportable segment focused on utilizing its PDC platform to develop drugs for the treatment of cancer.